Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

TriGemX Bio

PharmaDeviceNews TriGemX Bio

Editorial infographic showing TriGemX Bio’s planned $246 million SPAC transaction to support Phase 3 elismetrep trials, featuring laboratory imagery, clinical trial documents, financial charts, and key development milestones.

Pharma & Biotech

TriGemX Bio agrees $246m SPAC deal to advance elismetrep migraine trials

by Pallavi Madhiraju
October 20, 2026
0 Comments

TriGemX Bio plans a $246 million SPAC transaction to fund Phase 3 elismetrep trials. Clinical results and deal completion will determine its future.

Read More

Latest news and features

TriGemX Bio agrees $246m SPAC deal to advance elismetrep migraine trials
What the Veradermics Phase 3 results mean for oral minoxidil treatment
Summit Therapeutics expands ivonescimab development with SMT112-216 trial
United Therapeutics advances SUMMIT study targeting pulmonary hypertension in COPD
Zipalertinib controlled brain disease in 72% of patients. Could it address a major EGFR treatment gap?
Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer
ZAP Surgical secures $36m to expand ZAP-X brain radiosurgery
Faeth to present PIKTOR breast cancer data comparing multi-node cancer treatments
Gilead’s herpes candidate cut viral shedding by 98%. What will its latest IDWeek data reveal?
Merck is paying a 130% premium for Silence Therapeutics. Is divesiran the main prize?
GE HealthCare’s new ultrasound system is 26% faster in testing. Can it reduce imaging bottlenecks?
Sound Pharma reports Phase 3 hearing gains with SPI-1005, targeting sudden hearing loss

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Pulsed field ablation is emerging as a nonthermal alternative to radiofrequency and cryoballoon ablation, using targeted electrical pulses to isolate pulmonary veins while potentially reducing collateral tissue injury in atrial fibrillation treatment. Representative image.

Pharma & Biotech

Novartis pelacarsen fails 8,323-patient Phase 3 Lp(a)HORIZON cardiovascular trial

September 6, 2026

Latest business and industry news

EyePoint is cutting 53% of its workforce. Can DURAVYU’s DME trials rescue the strategy?
Dorchester Minerals is adding 4,300 royalty acres. Will the deal boost distributions?
Rocky Mountain Chocolate Factory (RMCF) explores sale after $6.6m deal
EBR Systems seeks Australian approval for WiSE wireless heart pacing device after US launch
Regis Resources holds A$1.28bn cash and bullion as McPhillamys court ruling reopens options

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.